Aspira Pathlab&Diagn

Aspira Pathlab & Diagnostics' board approved a rights issue to raise up to ₹65 crore from eligible shareholders, subject to shareholder and regulatory approvals. The issue could comprise equity shares or other convertible instruments, while the record date, price and entitlement ratio were left to a newly formed committee. The committee was chaired by Managing Director Nikunj Velji Mange and included Vaibhav Odhekar, Kiran Raghavendra Awasthi and Balkrishna Subhash Talawadekar. Revenue from operations was about ₹24.98 crore in FY26, with net profit of ₹5.13 lakh. Cash stood at ₹1.26 crore and bank deposits and fixed deposits at ₹3.21 crore at March 2026.

Powered by Tijori

Aspira Pathlab & Diagnostics' board approved a plan to raise up to ₹65 crore through a rights issue for eligible shareholders, subject to shareholder and regulatory approval. The instrument could be equity shares or other convertible securities, while the record date, issue price, entitlement ratio and other terms will be decided by a four-member committee. The board had deferred a fundraising proposal in August without taking a decision. Revenue from operations was ₹24.98 crore in FY26, while cash stood at ₹1.26 crore at March 2026 and the company reported a profit of ₹5.13 lakh.

Powered by Tijori

Aspira Pathlab & Diagnostics approved a rights issue of up to ₹65 crore, subject to shareholder and regulatory approvals, with the record date, price and entitlement ratio to be set later. The issue could comprise equity shares or convertible instruments, and a four-member committee was appointed to determine its terms. The board had deferred a fundraising proposal in August without taking a decision. FY26 operating revenue was about ₹25 crore and profit was ₹5.13 lakh, while cash and bank deposits stood at about ₹4.47 crore at March 2026.

Powered by Tijori

Aspira Pathlab scheduled a board meeting for September 12 to consider raising funds through equity shares, convertible warrants, a preferential issue, private placement, rights issue or other permitted methods, subject to approvals. The board had deferred a fundraising proposal at its August 12 meeting without taking a decision. Revenue for FY26 was about ₹25 crore, while profit after tax was ₹5.13 lakh. Borrowings stood at roughly ₹2.2 crore and retained earnings remained negative.

Powered by Tijori

Jay Arvind Bhanushali, a member of Aspira Pathlab & Diagnostics’ promoter group, bought 332 shares in the open market on 25 August, taking his holding to 744,797 shares, or 7.24%. His holding stood at 7.23% before the purchase, while the transaction represented 0.0032% of the company’s equity. The Bhanushali–Mange promoter group held 46% after the open offer completed in June. Aspira operated pathology and radiology diagnostic centres in Mumbai, Gujarat and Surat and reported revenue of about ₹25 crore in FY26.

Powered by Tijori

Aspira Pathlab & Diagnostics scheduled a board meeting for August 12, 2026 to consider and approve its unaudited standalone results for the quarter ended June 30 and a proposal to raise funds through equity shares, convertible warrants, a preferential issue, private placement, rights issue or other permitted instruments. No amount, pricing, investor or intended use of the proposed funds was specified.

Powered by Tijori

Aug 3 (Reuters) - Aspira Pathlab & Diagnostics Ltd ASPR.BO:

• ASPIRA PATHLAB & DIAGNOSTICS - PANKAJ JASHWANT SHAH RESIGNS AS MANAGING DIRECTOR

Source text: ID:nBSE6pR9z1

Further company coverage: ASPR.BO

(([email protected];))

April 4 (Reuters) - Aspira Pathlab & Diagnostics Ltd ASPR.BO:

• ASPIRA PATHLAB & DIAGNOSTICS LTD - CO ALONG WITH TWO OTHER DESIGNATED PARTNERS INCORPORATED LLP

Source text for Eikon: ID:nBSE8FwGRB

Further company coverage: ASPR.BO

(([email protected];))